A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer

Clinical Cancer Research

Volumn 12, Issue 23, 2006, Pages 7071-7078

  Dittrich, Christian ^a   Petruzelka, Lubos ^c   Vodvarka, Pavel ^d   Gneist, Margit ^a   Janku, Filip ^c   Kysela, Tamara ^d   Melemed, Allen ^b   Latz, Jane ^b   Simms, Lorinda ^b   Krejcy, Kurt ^b  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

^b ELI LILLY AND COMPANY   (United States)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Faculty Hospital and Policlinic Ostrava   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; FOLIC ACID; PEMETREXED;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CLINICAL TRIAL; DIARRHEA; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; METASTASIS; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLUTAMATES; GUANINE; HUMANS; INJECTIONS, INTRAVENOUS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 33845758522     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2829     Document Type: Article

References (31)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Shin C, Grindey GB, Barnett CJ, et al. Structure-activity relationship studies of novel pyrrolopyrimidine antifolate LY231514 [abstract]. Proc Am Assoc Cancer Res 1992;33:411.
3. Shih C, Gossett L, Gates S, et al. LY231514 and its polyglutamates exhibit potent inhibition against both human dihydrofolate reductase (DHFR) and thymidylate synthase (TS): multiple folate enzymes inhibition [abstract]. Ann Oncol 1996;7:85.
4. Grindey GB, Shih C, Barnett CJ, et al. LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS) [abstract]. Proc Am Assoc Cancer Res 1992;33:411.
5. Calvert H, Bunn PA. Pemetrexed, a novel multitargeted antifolate: current development and future directions. Semin Oncol 2002;29:1-61.
6. Niyikiza C, Baker S, Johnson R, Walling J, Seitz D, Allen R. MTA (LY231514): relationship of vitamin metabolite profile, drug exposure, and other patient characteristics to toxicity [abstract]. Ann Oncol 1998;9:126.
7. Niyikiza C, Hanauske AR, Rusthoven JJ, et al. Pemetrexed safety and dosing strategy. Semin Oncol 2002; 29:24-9.
8. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
9. Teicher BA, Chen V, Shih C, et al. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 2000;6: 1016-23.
10. Teicher BA, Alvarez E, Liu PC, et al. MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin Oncol 1999;26:55-62.
11. Miles DW, Smith IE, Coleman RE, Calvert AH, Lind MJ. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. Eur J Cancer 2001;37:1366-71.
12. Spielmann M, Martin M, Namer M, duBois A, Unger C, Dodwell DJ. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. Clin Breast Cancer 2001;2:47-51.
13. Martin M, Spielmann M, Namer M, et al. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann Oncol 2003;14: 1246-52.
14. Llombart-Cussac A, Theodoulou M, Rowland K, Lassus M, Cruciani S. A phase II trial of pemetrexed disodium (ALIMTA™, LY231514, MTA) in metastatic breast cancer (MBC) patients who have failed anthracyclines (A) and taxanes (T) (salvage chemotherapy) [abstract]. Breast Cancer Res Treat 2000;64:122.
15. O'Shaughnessy JA, Clark RS, Blum JL, et al. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer. Clin Breast Cancer 2005;6: 143-9.
16. Gomez HL, Hanauske A-R, Santillana S, et al. A phase II trial of pemetrexed in previously untreated breast cancer [abstract]. Proc Am Soc Clin Oncol 2002;21:57a.
17. Colvin M. Cyclophosphamide and analogues. In: Crooke ST, Prestayko AS, editors. Cancer and chemotherapy. New York: Academic Press: 1981. p. 25-38.
18. Wall RL, Conrad FG. Cyclophosphamide therapy. Its use in leukemia, lymphoma, and solid tumors. Arch Intern Med 1961;108:456-82.
19. Gordon I, McArthur J. Thiotepa and cyclophosphamide in the treatment of advanced mammary cancer. Scott Med J 1965;10:27-33.
20. Carter SK, Livingston RB. Cyclophosphamide in solid tumors. Cancer Treat Rev 1975;2:295-322.
21. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294: 405-10.
22. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-6.
23. Joensuu H. Treatment of locally advanced and metastatic breast cancer. In: Souhami RL, Tannock I, Hohenberger P, Horiot J-C, editors. Oxford textbook of oncology. 2nd ed. New York: Oxford University Press; 2002. p. 1763-89.
24. Cancer Therapy Evaluation Program. Common Toxicity Criteria, version 2.0. DCTD, NCI, NIH, DHHS; 1998.
25. Latz, JE, Chaudhary A, Ghosh A, Johnson RD. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 2006;57:401-11.
26. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions, and toxicity criteria. Invest New Drugs 1992;10:239-53.
27. Nakagawa K, Kudoh S, Matsui K, et al. A phase I study of pemetrexed supplemented with folic acid (FA) and vitamin b12 (VB12) in Japanese patients with solid tumors [abstract]. Eur J Cancer 2004; 2:148.
28. Hammond LA, Forero L, Beeram M, et al. Phase 1 study of pemetrexed (LY231514) with vitamin supplementation in patients with locally advanced or metastatic cancer [abstract]. Proc Am Soc Clin Oncol 2003;22:133.
29. Hanauske A-R, Dittrich C, Otero J. Overview of phase I/II pemetrexed studies. Oncology 2004;18: 18-25.
30. Frei E III, Antman KH. Principles of dose, schedule, and combination chemotherapy. In: Bast RC, Kufe DW, Pollock RE, et al, editors. Cancer medicine. 5th ed. London: BC Decker; 2000. p. 556-68.
31. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;7:545-52.